RxDoctor Payments Data

Christine Joanne del Prado-Rico, MD

Pulmonary Disease · Anderson, SCNPI 1992292510

Payments from drug & device makers

$470in general payments, 2019–2025

Across 17 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$102
  • Sanofi$70
  • GSK$46
  • Regeneron Healthcare Solutions, Inc.$38
  • United Therapeutics Corporation$29
  • Actelion Pharmaceuticals US, Inc.$28
  • plus $157 from 8 others

What the payments were for

  • Food & beverage$470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$470 in reported general payments places this provider in the 15th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$28,565
Medicare patients
132
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko12$55,280
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$31,349
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$19,697
Spiriva RespimatTiotropium Bromide18$18,187
Spiriva HandihalerTiotropium Bromide15$10,499
Advair HfaFluticasone Propion/Salmeterol22$8,770
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$8,572
SymbicortBudesonide/Formoterol Fumarate25$7,795
Breo ElliptaFluticasone/Vilanterol16$6,325
Incruse ElliptaUmeclidinium Bromide13$5,251
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$4,930
DuleraMometasone/Formoterol11$3,859
Arnuity ElliptaFluticasone Furoate14$3,527
Albuterol Sulfate HfaAlbuterol Sulfate90$2,586
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$102$82,77265 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$46$55,02497 claims
MerckDulera$14$3,85911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →